ADVERTISEMENT

Custom Search
ADVERTISEMENT
Helpdesk Support
Today's Health Headlines
WASHINGTON (Reuters) - President Donald Trump made calls to fellow Republicans in the U.S. Senate on Friday to mobilize support for their party's healthcare overhaul while acknowledging the legislation is on a "very, very narrow path" to passage.

CHICAGO (Reuters) - The U.S. Department of Agriculture has found repeated import violations in raw Brazilian beef, including abscesses and unidentified foreign material, a top agency official said, explaining reasons for a U.S. ban on imports of fresh Brazilian beef.

NEW YORK (Reuters) - Health insurers are concerned about the U.S. Senate's plans to cut the Medicaid program for the poor and the impact such a move would have on state governments, the industry's largest lobbyist said on Friday.

ZURICH (Reuters) - A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.

(Reuters) - A handful of drugmakers are taking their first steps toward developing marijuana-based painkillers, alternatives to opioids that have led to widespread abuse and caused the U.S. health regulator to ask for a withdrawal of a popular drug this month.

DUBAI (Reuters) - Saudi Arabia's crown prince has donated $66.7 million to combat a cholera epidemic in Yemen, where a Saudi-led coalition is fighting in a war blamed for causing a humanitarian disaster.

PORT-AU-PRINCE, Haiti (Reuters) - The United Nations stressed on Thursday its support for eradicating cholera in Haiti, an epidemic it accidentally started, although the government said residents would be better served if aid funding was channeled through it.

WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people with severe conditions.

(Reuters Health) - Meeting some or all of the American Heart Association’s seven ideal cardiovascular health goals is associated with longer life and fewer heart attacks and strokes, no matter your age.

ADVERTISEMENT
Welcome Guest
Username: 
Password:
Not a member? Sign Up!
Browse RSS Feeds
click here when finished
Save Page Layout
Video
ADVERTISEMENT
loading